Cyclophosphamide, Alvocidib (Flavopiridol), and Rituximab, a Novel Feasible Chemoimmunotherapy Regimen for Patients with High-Risk Chronic Lymphocytic Leukemia

Alvocidib has demonstrated efficacy in high-risk chronic lymphocytic leukemia (CLL) patients. In this phase I study, we combined cyclophosphamide, alvocidib and rituximab (CAR) in a schema designed to mitigate tumor lysis syndrome (TLS) seen previously with alvocidib. Nine nucleoside analog-naïve, h...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Stephens, Deborah M., Ruppert, Amy S., Maddocks, Kami, Andritsos, Leslie, Baiocchi, Robert, Jones, Jeffrey, Johnson, Amy J., Smith, Lisa L., Zhao, Yuan, Ling, Yonghua, Li, Junan, Phelps, Mitch A., Grever, Michael R., Byrd, John C., Flynn, Joseph M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3934299/
https://ncbi.nlm.nih.gov/pubmed/23867058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.06.006
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller